---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030764"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:16:51.990940+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar initiates Phase 1a trial of MNPR-101-Lu radiopharmaceutical therapy in advanced cancers

## Summary
- Phase 1a open-label dose-escalation study of MNPR-101-Lu in solid tumors now recruiting.
- First site activated: Melbourne Theranostic Innovation Centre in Australia.
- Trial open only to patients in ongoing MNPR-101-Zr Phase 1 imaging/dosimetry trial.
- MNPR-101 targets uPAR, expressed in pancreatic, breast, colorectal, ovarian, and bladder cancers.
- CEO says trial launched months ahead of original schedule.

## SEC filing metadata
- accession: 0001437749-24-030764
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924030764/0001437749-24-030764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924030764/mnpr20241004_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030764
- JSON: https://secwatch.observer/filing/0001437749-24-030764.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.